Born from Institut Curie's incubation program, One Biosciences is a start-up specialized in leveraging the power of single-cell analysis to unlock a new wave of targets and precision medicines for a broad range of difficult-to-treat conditions. One Biosciences is an integrated discovery engine combining a multi-disciplinary team with in-house computational capabilities.
Year of creation: 2020
Line of business: Precision medicine, Artifical Intelligence
Institut Curie: Incubator, institutional co-founder and R&D partner
One Biosciences is an integrated ‘discovery engine’ composed of multidisciplinary teams, gathering data scientists, clinicians and biologists. The teams focus on understanding the causes of selected diseases by grasping the heterogeneity of complex biological systems, revealing rare cell populations, and enabling the cellular mapping of such diseases.
1. The collecting of tissues related to disease of interest.
2. The dissociation and sequencing at single-cell level.
3. The analysis and interpretation to generate new insights
Single-cell approaches are a paradigm shift, enabling unprecedented granularity to understand the living - human development and cancer - at a new scale. These approaches now allow to tackle problems that were previously untraceable and to dare exploring novel therapeutic solutions for difficult-to-treat diseases, especially in the field of oncology.
One Biosciences aims to discover transcriptomic biomarkers and new actionable targets and become a leader in precision therapies for difficult-to-treat diseases, leveraging the power of single-cell technologies.
More about One Biosciences: